To evaluate the in vivo impact of the tumor-derived heterozygous RAC1A159V/WT mutant on the TIME and ICI response, CT26 RAC1WT/WT and heterozygous RAC1A159V/WT cells were subcutaneously injected into syngeneic BALB/c mice and treated with anti-PD1 or IgG isotype control every other day after tumors became palpable (Fig. 7J). This evidence concerns the gene DDX53 and neoplasm.